The epidemiology and clinical significance of fluconazole resistance were assessed in a cohort of advanced human immunodeficiency virus (HIV)-infected patients with recurrent oropharyngeal candidiasis. Fifty patients were prospectively evaluated using a novel method of detecting fluconazole resistance with chromogenic media containing fluconazole; results were confirmed with macrobroth testing. Resistant yeasts, defined as MICs~8 pg/mL, were detected in 16 (32%) of 50 patients: 7 (14%) had resistant Candida albicans, 7 (14%) had resistant non-C. albicans yeast, and 2 (4%) had mixed resistant yeasts. MICs were~32 in 11 of 16 isolates. Previous fluconazole use and severe immunosuppression were risk factors for resistance. However,S of 26 patients had resistant isolates with no prior fluconazole use, and all were severely immunosuppressed. Despite the high prevalence of resistance, 48 patients clinically responded to fluconazole. Fluconazole-resistant C. albicans and non -C. albicans yeast infections are common in patients with advanced immunodeficiency, but clinical efficacy of fluconazole remains high.
Detection and Significance of Fluconazole Resistance in Oropharyngeal Candidiasis in Human Immunodeficiency Virus-Infected Patients
The epidemiology and clinical significance of fluconazole resistance were assessed in a cohort of advanced human immunodeficiency virus (HIV)-infected patients with recurrent oropharyngeal candidiasis. Fifty patients were prospectively evaluated using a novel method of detecting fluconazole resistance with chromogenic media containing fluconazole; results were confirmed with macrobroth testing. Resistant yeasts, defined as MICs~8 pg/mL, were detected in 16 (32%) of 50 patients: 7 (14%) had resistant Candida albicans, 7 (14%) had resistant non-C. albicans yeast, and 2 (4%) had mixed resistant yeasts. MICs were~32 in 11 of 16 isolates. Previous fluconazole use and severe immunosuppression were risk factors for resistance. However,S of 26 patients had resistant isolates with no prior fluconazole use, and all were severely immunosuppressed. Despite the high prevalence of resistance, 48 patients clinically responded to fluconazole. Fluconazole-resistant C. albicans and non -C. albicans yeast infections are common in patients with advanced immunodeficiency, but clinical efficacy of fluconazole remains high.
Oropharyngeal candidiasis (OPC) is the most common fungal infection in patients infected with the human immunodeficiency virus (HIV).
It can cause significant morbidity, with dysphagia and odynophagia leading to poor nutritional intake, weight loss, and inanition. Oropharyngeal candidiasis is an important marker for significant immunosuppression and is a risk factor for progression to AIDS [1 -5] . It is often the initial clinical manifestation of HIV infection [1] , and with progression of immunodeficiency, more severe infection is a common clinical presentation.
Currently, there are many effective therapeutic options for OPC. The newer azole antifungal compounds are commonly used because of their high rate of efficacy, ease of administration, and low toxicity [6] [7] [8] . More recently, fluconazole, the most commonly used newer azole, has been found to be an extremely effective, very well-tolerated, and simple treatment [7] [8] [9] . As a result, fluconazole has been widely used to treat OPC, both for acute episodes (intermittent therapy) and for cies, such as Candida krusei and Candida (Torulopsis) glabrata, which are inherently less susceptible in vitro to fluconazole, are being increasingly isolated from OPC patients [14] [15] [16] .
In addition, recently there have been several reports of C. albicans with decreased susceptibility to fluconazole [12, [17] [18] [19] [20] [21] [22] . Advanced immunosuppression and previous fluconazole use have been associated with the detection of yeasts requiring elevated MICs [16, 20, 21, 23, 24] . The ability to screen for resistant isolates quickly and easily would help to characterize the epidemiology and aid in the treatment of these patients. Recently, we developed a method that uses the addition of fluconazole to a new chromogenic medium, CHROMagar Candida, which distinguishes Candida species based on colony color. The addition of fluconazole to this medium allows for rapid detection of fluconazole-resistant isolates based on colony morphology [25] . This allows excellent correlation with the National Committee for Clinical Laboratory Standards (NCCLS) macrobroth method [26] in identifying resistant yeast isolates.
This study was designed to assess the importance of detecting fluconazole-resistant yeasts in OPC and to determine the clinical significance of yeasts with reduced in vitro susceptibility to fluconazole. In addition, risk factors for the development of fluconazole resistance were assessed. The study population was a cohort of HIV -infected patients with active OPC who were enrolled in a prospective study to determine the significance of fluconazole-resistant yeasts and the efficacy of fluconazole in patients with resistant isolates.
Materials and Methods
Revankar et a!.
JID 1996;174 (October) The HIV-infected patients enrolled in this study represented a severely immunosuppressed population as indicated by the mean and median CD4 cell counts of 37 and 23, respectively (table 1). In addition, >75% of the patients had at least 1 major opportunistic infection, with almost a third of the patients having had~2 opportunistic infections before study entry. Almost all of the patients were men (96%). Half of the patients studied were Hispanic, reflecting the ethnicity of the area; 38% were white, non-Hispanic; 12% were African-American.
Almost half of the patients (24/50) had received fluconazole in the previous year (table 1). Thirteen had received it~I month as continuous treatment. Fluconazole doses ranged from 50 to 400 mg/day. Eleven patients received intermittent therapy, which was given only during relapses of Ol'C, Of the patients previously receiving fluconazole, 13 had no resistant isolates and had received fluconazole for a mean of 77 days (median, 50; range, 10-248) or 10.4 g (median, 7.0; range, HIV-infected patients were enrolled from a population followed at the University Health System and the Audie L. Murphy VA Hospital, San Antonio, Texas. The entry requirements were evidence of HIV seropositivity, CD4 cell count <350/mm 3 , and active OPC at the time of initial assessment.
Oropharyngeal cultures were obtained by both direct swab of OPC lesions and oral swish samples using 10 mL of sterile saline. These clinical specimens were then plated on two types of solid media with and without fluconazole to isolate resistant populations of yeasts. RPMI 1640 nutrient medium (Mediatech, Washington, DC) was prepared at double standard concentration and added to an equal volume of double-concentrated Bacto agar (Difco, Detroit). A novel chromogenic medium, CHROMagar Candida (CHROMagar, Paris), was prepared according to manufacturer's instructions. CHROMagar allows presumptive identification of different Candida species based on colony color and morphology [26] . Fluconazole was added to the liquid suspensions of the above media to give final concentrations of 8 and 16 Mg/mL in agar.
Resistant isolates could be detected on fluconazole-containing plates as growth that was identical to growth on plates without fluconazole. Susceptible isolates were pinpoint in size on media containing fluconazole compared to the same isolates on media without fluconazole, as described [25] . Multiple isolates from each culture sample, including both resistant-and susceptible-appearing colonies, were submitted for 48-h macrobroth MIC determination by the NCCLS method [27] . These susceptibility tests were done at the Fungus Testing Laboratory, University of Texas Health Science Center at San Antonio. A 48-h macrobroth MIC~8 J1g/ mL by the NCCLS method was considered resistant for the purposes of this study.
A retrospective chart review was done for each patient, noting CD4 cell count, previous opportunistic infections, and amount of fluconazole and other antifungal therapy taken by the patient over the previous 12 months. Intermittent therapy was defined as treatment for <21 days for each relapse of thrush, and continuous therapy was considered to be treatment for~30 days. The amount of fluconazole was calculated as the total number of days taken and the total amount in grams taken. To stratify patients according to level of immunosuppression, a simple staging system was devised. The staging system is based on the concept that major opportunistic infections are an important marker of the degree of immunosuppression, in addition to CD4 cell count. This system assigned a point value to two clinical criteria, CD4 cell count and number of prior AIDS-defining opportunistic infections, as follows: 0 points for CD4 cell count > 50, 1 point for CD4 cell count ::;:;50,0 points for no prior opportunistic infections, 1 point for I prior opportunistic infection, and 2 points for~2 prior opportunistic infections. A total score of 0 or 1 was considered mild immunosuppression and a score of 2 or 3 was considered severe immunosuppression.
Patients were treated with oral fluconazole at 100 mg/day for 7 days and increased as needed (up to 800 mg/day) to achieve clinical response, which was defined as complete resolution of symptoms (burning, dysphagia, dysgeusia) and clearance of lesions by visual inspection. Oropharyngeal cultures were obtained at initiation of treatment and at weekly intervals during treatment, as described (23) 48 (96) 2 (4) 25 (50) 19 (38) 6 (12) II (22) 23 (46) 16 (32) 24 (48) 11 (22) 13 (26) 12 (24) 3 (6) 3 (6) 6 (12) .lg/mL. Two thirds of these had isolates with MICs ?;:32 p,g/mL. Resistant C. albicans were seen in 7 (14%) patients, and resistant non-Co albicans yeasts were seen in 7 (14%). Two patients (4%) had both C. albicans and non-Co albicans resistant isolates. Of patients with resistant isolates, 11 (69%) of 15 had received fluconazole before the study. Of the remaining patients with only susceptible isolates (MIC :0:;4 p,g/ mL), only 13 (38%) of 34 had previously received fluconazole Fifteen patients were considered mildly immunosuppressed, and of these, only 3 (20%) had a yeast isolate with a MIC~8 f..lg/mL. Two of these isolates were C. albicans. In contrast, 13 (37%) of 35 patients who were considered severely immunosuppressed had yeast isolates with MICs ?;: 8 f..lg/mL (P = .19). Three of 4 patients in each immunosuppression group who received> 10 g of fluconazole in the previous year had resistant isolates.
The role of mild versus severe immunosuppression was not statistically significant (P = .19) in the development of resistant
isolates, but when the use of fluconazole was controlled for, there was a trend toward significance, although the sample sizes are small. .5. A study by Fan-Havard et al. [14] did not demonstrate an increase in yeast MICs with thrush prophylaxis, although only 3 patients received an unspecified amount of fluconazole. A recent study by Millon et al. [28] showed that the total amount of fluconazole taken was an important factor in the development of resistant isolates in OPC; patients who had received > 109 of fluconazole were more likely to have developed yeast populations with increased MICs. Powderly et al. [18] followed 22 HI V-positive patients with recurrent thrush and found that those with lower CD4 cell counts « 100) had different strains and species (non-C. albicans yeasts) causing clinical relapses. In contrast, Heald et al. [31] suggested that patients with continuous treatment had lower rates of resistance.
In the present study, the presence of C. albicans with MICs 8 j.lg/mL was seen in patients regardless of their prior fluconazole use, except for the least immunosuppressed. Of interest, however, 3 patients in our study received> lag of fluconazole but did not have resistant yeast isolates on culture. Two of these patients were in the mild immunosuppression group. This may suggest that prior fluconazole use alone is not the only factor for developing resistance.
The percentage of yeasts with MICs~8 j.lg/mL was higher in patients with prior fluconazole use (11/24), but fluconazole resistance was also detected in 5 (19%) of 26 patients with no previous fluconazole use. Our findings suggest that the level of immunosuppression, as measured by the simple staging system outlined above, may also play an important role, in addition to prior fluconazole use, in the emergence of microbiologic resistance in OPC in this patient population.
Maenza et al. [23] showed the importance of fluconazole resistance in patients who do not respond to fluconazole treatment, but in this study with intensive screening using fluconazole-containing agar plates and CHROMagar chromogenic me- dia, resistance (as defined by MIC~8 j.Lg/mL) did not predict clinical failure of fluconazole. Clinical efficacy was seen in 11 of 13 patients with a MIC~32 despite the presence of yeasts with reduced susceptibility to fluconazole in these patients. Almost all patients responded clinically to fluconazole, and most were treated with fluconazole at 100 mg/day for 7 days. The 2 patients who did not clinically respond had a predominance of yeasts with MICs~64 j..ig/mL. In other patients with isolates with MICs~64 j..ig/mL, resistant isolates were generally found in a small percentage ofthe total number of isolates. In patients with mixed susceptible and resistant yeasts, good clinical responses occurred. Thus, the presence of resistant yeast isolates alone in OPC may not always be predictive of clinical fluconazole resistance, particularly if predominant isolates are susceptible to clinically achievable levels of fluconazole. In patients with mixed cultures, resistant isolates may not be responsible for clinical symptoms. Clinical resistance may also be more accurately defined by a higher MIC value than 8 j..ig/mL, reflecting the ability of high-dose fluconazole to treat yeasts with MICs ?8 J.1;g/mL. The break point of 8 j.Lg/mL is not established, but preliminary guidelines suggest a break point of 8 j..ig/mL at 100 mg of fluconazole, which was most commonly used in this study.
Our results confirm other studies that show a high prevalence of yeast isolates from OPC with reduced susceptibility to fluconazole in late-stage HIV-infected patients. Both C. albicans and non-C. albicans yeasts were found. Thirty-two percent of the patients in our study had a yeast isolate with a MIC~8 j.Lg/mL, with 18% having a resistant non -C. albicans isolate and 18% with resistant C. albicans. Though all the patients in this study had AIDS as defined by CD4 cell count <200, most of the patients with resistant isolates were among the more severely immunosuppressed, as described by the above staging system. Prior fluconazole use, especially > 109, did appear to be a risk factor for the development of resistant isolates, especially C. albicans. However, it did not consistently predict resistance.
Advanced immunosuppression also appeared to be a predictor of the presence of resistant isolates in oropharyngeal cultures, independent of fluconazole use, and may partly explain resistance in those patients who had taken little or no prior fluconazole. It is also possible that they may have acquired resistant isolates from other persons with OPC.
The fact that almost all patients responded to fluconazole suggests that microbiologic resistance in OPC may not always be predictive of clinical response to fluconazole. Other factors, such as immunosuppression and predominance of the resistant isolates in culture, appear to influence clinical response to flu-conazole therapy. Results of this study suggest that routine use of culture and susceptibility testing in treating OPC is not indicated. However, patients may not always respond to increasing doses of fluconazole [19] . In those patients, it may be useful to obtain cultures to document the susceptibility and identity of the organism to guide future treatment.
In summary, microbiologic resistance of C albicans and non-C albicans yeasts in oropharyngeal candidiasis in HIVpositive patients is common, especially in those patients with advanced immunosuppression. Both the level of immunosuppression and previous fluconazole use are important in the emergence of microbiologic resistance of yeast isolates in this disease. In addition, > 10 g of prior fluconazole use was associated with C albicans isolates with MICs~8 f.lg/mL, but resistance was more frequently seen in more severely immunosuppressed patients. Clinical outcomes with fluconazole overall were excellent. Further prospective studies are required to define the clinical importance of fluconazole-resistant yeasts.
